Midlands Oncology Ltd 12082230 false 2024-08-01 2025-07-31 2025-07-31 The principal activity of the company is oncological services Digita Accounts Production Advanced 6.30.9574.0 true true 12082230 2024-08-01 2025-07-31 12082230 2025-07-31 12082230 bus:Director2 1 2025-07-31 12082230 core:RetainedEarningsAccumulatedLosses 2025-07-31 12082230 core:ShareCapital 2025-07-31 12082230 core:FinancialAssetsCostLessImpairment core:Non-currentFinancialInstruments 2025-07-31 12082230 core:CurrentFinancialInstruments 2025-07-31 12082230 core:CurrentFinancialInstruments core:WithinOneYear 2025-07-31 12082230 core:OtherResidualIntangibleAssets 2025-07-31 12082230 core:FurnitureFittingsToolsEquipment 2025-07-31 12082230 core:MotorVehicles 2025-07-31 12082230 bus:SmallEntities 2024-08-01 2025-07-31 12082230 bus:AuditExemptWithAccountantsReport 2024-08-01 2025-07-31 12082230 bus:FilletedAccounts 2024-08-01 2025-07-31 12082230 bus:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 12082230 bus:RegisteredOffice 2024-08-01 2025-07-31 12082230 bus:Director2 2024-08-01 2025-07-31 12082230 bus:Director2 1 2024-08-01 2025-07-31 12082230 bus:Director3 2024-08-01 2025-07-31 12082230 bus:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 12082230 bus:Agent1 2024-08-01 2025-07-31 12082230 core:IntangibleAssetsOtherThanGoodwill 2024-08-01 2025-07-31 12082230 core:OtherResidualIntangibleAssets 2024-08-01 2025-07-31 12082230 core:ComputerEquipment 2024-08-01 2025-07-31 12082230 core:FurnitureFittings 2024-08-01 2025-07-31 12082230 core:FurnitureFittingsToolsEquipment 2024-08-01 2025-07-31 12082230 core:MotorVehicles 2024-08-01 2025-07-31 12082230 core:PlantMachinery 2024-08-01 2025-07-31 12082230 countries:AllCountries 2024-08-01 2025-07-31 12082230 2024-07-31 12082230 bus:Director2 1 2024-07-31 12082230 core:OtherResidualIntangibleAssets 2024-07-31 12082230 core:FurnitureFittingsToolsEquipment 2024-07-31 12082230 core:MotorVehicles 2024-07-31 12082230 2023-08-01 2024-07-31 12082230 2024-07-31 12082230 bus:Director2 1 2024-07-31 12082230 core:RetainedEarningsAccumulatedLosses 2024-07-31 12082230 core:ShareCapital 2024-07-31 12082230 core:CurrentFinancialInstruments 2024-07-31 12082230 core:CurrentFinancialInstruments core:WithinOneYear 2024-07-31 12082230 core:OtherResidualIntangibleAssets 2024-07-31 12082230 core:FurnitureFittingsToolsEquipment 2024-07-31 12082230 core:MotorVehicles 2024-07-31 12082230 core:PreviouslyStatedAmount 2024-07-31 12082230 bus:Director2 1 2023-08-01 2024-07-31 12082230 bus:Director2 1 2023-07-31 iso4217:GBP xbrli:pure

Registration number: 12082230

Midlands Oncology Ltd
Unaudited Filleted Financial Statements
for the Year Ended 31 July 2025

Midlands Oncology Ltd

Contents

Company Information | 1
Balance Sheet | 2
Notes to the Unaudited Financial Statements | 3 to 7

Midlands Oncology Ltd

Company Information

Directors | Dr R K Dandamudi A Dandamudi

Registered office | 11c Kingswood Road Hampton Lovett Droitwich Worcestershire WR9 0QH

Accountants | Ballards LLP Chartered AccountantsOakmoore Court 11C Kingswood Road Hampton Lovett Droitwich Worcestershire WR9 0QH

Midlands Oncology Ltd

(Registration number: 12082230)
Balance Sheet as at 31 July 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Intangible assets | 4 | 286 | 357
Tangible assets | 5 | 13,485 | 16,556
Other financial assets | 6 | 43,544 | -
|  | 57,315 | 16,913
Current assets |  |  |
Debtors | 7 | 48,575 | 63,346
Cash at bank and in hand |  | 171,143 | 157,868
|  | 219,718 | 221,214
Creditors: Amounts falling due within one year | 8 | (13,956) | (12,133)
Net current assets |  | 205,762 | 209,081
Net assets |  | 263,077 | 225,994
Capital and reserves |  |  |
Called up share capital |  | 100 | 100
Retained earnings |  | 262,977 | 225,894
Shareholders' funds |  | 263,077 | 225,994

For the financial year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 13 March 2026 and signed on its behalf by:

......................................... Dr R K Dandamudi Director |  |

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

1 | General information

The company is a private company limited by share capital, incorporated in UK.

The address of its registered office is:
11c Kingswood Road
Hampton Lovett
Droitwich
Worcestershire
WR9 0QH
Great Britain

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Computer Equipment | 33.3% Reducing balance
Fixtures and Fittings | 25% Reducing Balance
Plant and Machinery | 25% Reducing Balance

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class | Amortisation method and rate
Other intangible assets | 10% Straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 3 (2024 - 3).

4 | Intangible assets

| Other intangible assets £ | Total £
Cost or valuation
At 1 August 2024 | 714 | 714
At 31 July 2025 | 714 | 714
Amortisation
At 1 August 2024 | 357 | 357
Amortisation charge | 71 | 71
At 31 July 2025 | 428 | 428
Carrying amount
At 31 July 2025 | 286 | 286
At 31 July 2024 | 357 | 357

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

5 | Tangible assets

| Furniture, fittings and equipment £ | Motor vehicles £ | Total £
Cost or valuation
At 1 August 2024 | 11,528 | 17,555 | 29,083
Additions | 2,026 | - | 2,026
Disposals | (996) | - | (996)
At 31 July 2025 | 12,558 | 17,555 | 30,113
Depreciation
At 1 August 2024 | 8,138 | 4,389 | 12,527
Charge for the year | 1,642 | 3,291 | 4,933
Eliminated on disposal | (832) | - | (832)
At 31 July 2025 | 8,948 | 7,680 | 16,628
Carrying amount
At 31 July 2025 | 3,610 | 9,875 | 13,485
At 31 July 2024 | 3,390 | 13,166 | 16,556

6 | Other financial assets (current and non-current)

| Financial assets at cost less impairment £ | Total £
Non-current financial assets
Cost or valuation
Additions | 43,544 | 43,544
At 31 July 2025 | 43,544 | 43,544
Impairment
Carrying amount
At 31 July 2025 | 43,544 | 43,544

Midlands Oncology Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

7 | Debtors

Current | 2025 £ | 2024 £
Trade debtors | 4,842 | 3,117
Other debtors | 43,733 | 60,229
| 48,575 | 63,346

8 | Creditors

| 2025 £ | 2024 £
Due within one year |  |
Other creditors | 13,956 | 12,133

9 | Related party transactions

Transactions with directors

2025 | At 1 August 2024 £ | Advances to director £ | Repayments by director £ | At 31 July 2025 £
Dr R K Dandamudi
| 60,227 | 79,562 | (96,055) | 43,734

2024 | At 1 August 2023 £ | Advances to director £ | Repayments by director £ | At 31 July 2024 £
Dr R K Dandamudi
| 173,279 | 99,018 | (212,070) | 60,227

Directors' remuneration

The directors' remuneration for the year was as follows:

| 2025 £ | 2024 £
Remuneration | 4,190 | -
Contributions paid to money purchase schemes | 63 | -
| 4,253 | -